- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.10. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 51 | GlobeNewswire (Europe) | WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing... ► Artikel lesen | |
| 17.09. | Citizens analyst reiterates Market Outperform rating on Acrivon stock | 2 | Investing.com | ||
| 17.09. | Acrivon: Citizens JMP bestätigt "Market Outperform" und Kursziel von 13 US-Dollar | 1 | Investing.com Deutsch | ||
| 05.09. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 13.08. | Acrivon Therapeutics GAAP EPS of -$0.55 | 1 | Seeking Alpha | ||
| 13.08. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights | 214 | GlobeNewswire (Europe) | Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and... ► Artikel lesen | |
| 13.08. | Acrivon Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 13.06. | Acrivon Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| ACRIVON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.05. | Acrivon Therapeutics GAAP EPS of -$0.51 beats by $0.10 | 3 | Seeking Alpha | ||
| 15.05. | Cantor Fitzgerald maintains Overweight on Acrivon Therapeutics stock | 2 | Investing.com | ||
| 14.05. | Acrivon Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 14.05. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | 605 | GlobeNewswire (Europe) | Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of... ► Artikel lesen | |
| 05.05. | Piper Sandler sets $6 target for Acrivon stock, rates it Overweight | 1 | Investing.com | ||
| 25.04. | Acrivon Therapeutics, Inc: Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 | 2 | GlobeNewswire (USA) | ||
| 07.04. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer | 225 | GlobeNewswire (Europe) | Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of... ► Artikel lesen | |
| 27.03. | Acrivon Therapeutics, Inc: Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results | 185 | GlobeNewswire (Europe) | Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects R&D event highlighted positive... ► Artikel lesen | |
| 16.10.24 | Acrivon Therapeutics, Inc: Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 157 | GlobeNewswire (Europe) | WATERTOWN, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon... ► Artikel lesen | |
| 11.10.24 | Acrivon Therapeutics, Inc: Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity | 178 | GlobeNewswire (Europe) | - First patient dosed two quarters ahead of original timelines in Acrivon Phase 1 study to assess safety and tolerability of ACR-2316 - ACR-2316 was internally discovered and advanced in 15 months... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,10 | -0,28 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| CUREVAC | 4,678 | +0,09 % | CureVac SCHOCKIERT Anleger: Könnte die Aktie JETZT komplett einbrechen - Dringend vor dem Wochenende handeln! | ||
| AMGEN | 256,15 | +0,22 % | Amgen Launches AmgenNow, Direct-to-patient Program; Available To Repatha Patients | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha or evolucumab. Repatha will be available through AmgenNow at a... ► Artikel lesen | |
| NOVAVAX | 7,461 | +0,47 % | Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU | ||
| BIOGEN | 128,05 | -1,08 % | Erste Patienten bekommen Alzheimer-Mittel Lecanemab der Hersteller Biogen und Eisai | BERLIN (dpa-AFX) - Seit gut einem Monat ist das Alzheimer-Medikament Lecanemab der Hersteller Biogen und Eisai in Deutschland verfügbar - inzwischen haben erste Patientinnen und Patienten mit der Therapie... ► Artikel lesen | |
| MAINZ BIOMED | 1,520 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed berichtet Topline-Ergebnisse aus der Machbarkeitsstudie zum Biomarker-Panel im Rahmen seines Bauchspeicheldrüsenkrebs-Projekts | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Studienergebnisse
Mainz Biomed berichtet Topline-Ergebnisse aus der Machbarkeitsstudie zum Biomarker-Panel im Rahmen... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,900 | +2,10 % | Why Shares in Viking Therapeutics Surged This Week | ||
| INTELLIA THERAPEUTICS | 21,870 | -0,73 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| TEMPUS AI | 85,00 | -1,16 % | AKTIONÄR-Tipp Tempus AI: Rücksetzer nach Allzeithoch - so sollten Sie jetzt handeln | Der Megatrend Künstliche Intelligenz (KI) beherrscht weiterhin das Börsengeschehen. Kaum ein Tag vergeht, an dem keine milliardenschweren Deals oder Investitionen angekündigt werden. Von der positiven... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,338 | +0,99 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 20,370 | +1,80 % | Sarepta Therapeutics, Inc.: Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress | Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the 30th Annual Congress of the World Muscle Society (WMS) 2025 Congress, taking... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 46,790 | +0,45 % | 6 Analysts Assess BioMarin Pharmaceutical: What You Need To Know | ||
| EXELIXIS | 33,250 | -0,33 % | Adagene Inc.: Adagene Expands SAFEbody Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate | SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis.... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,960 | +2,24 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,319 | 0,00 % | PacBio Stock Dips Despite Announcing Expanded Partnership With seqWell |
ACRIVON THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,980 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACRIVON THERAPEUTICS INC finden Sie auf Wallstreet Online.